0.18
+12.58%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Vistagen Therapeutics
From its filings with the US Securities and Exchange Commission
Vistagen Therapeutics is based in South San Francisco, California and is incorporated in Nevada. Its shares trade on Nasdaq under the ticker VTGN. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 March 2026, it reported revenue of $1.3m and a net loss of $69.7m. At that date it held total assets of $48.6m and shareholders' equity of $35.5m.
We are a late clinical-stage therapeutics company focused on developing and potentially commercializing new medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. Each of the five clinical-stage intranasal pherine product candidates in our neuroscience pipeline has a novel neurocircuitry-focused proposed mechanism of action (MOA) and at least one positive clinical study in its targeted patient population. Leveraging our deep understanding of nose-to-brain neurocircuitry, we have designed our intranasal pherine product candidates are designed to rapidly, specifically and selectively bind to peripheral receptors in human nasal chemosensory neurons and rapidly activate neurocircuits believed to regulate brain areas, without requiring systemic absorption or uptake into the brain to achieve desired therapeutic benefits.
Our most advanced intranasal pherine product candidate, fasedienol, is being investigated in a U.S. Phase 3 development program for the acute treatment of social anxiety disorder. Itruvone is being developed for treatment of major depressive disorder, refisolone for the treatment of moderate to severe vasomotor symptoms (hot flashes) due to menopause, PH15 for improvement of psychomotor impairment due to mental fatigue and PH284 for the treatment of cancer cachexia.
Quoted from its 10-K, filed 15 Jun 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 18 Oct 2010
- Employees
- 9
- Website
- vistagen.com ↗
- Head office
- 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080
- Incorporated in
- NV
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Ms. Margaret FitzpatrickIndependent Chairman of the Board$133,726
- Mr. Shawn SinghPresident, Chief Executive Officer, Director, since 2011$2.5m
- Mr. Nick TresslerChief Financial Officer, Treasurer
- Mr. Joshua PrinceChief Operating Officer$1.1m
- Mr. Reid AdlerChief Legal Officer$1.2m
- Ms. Elissa CoteChief Corporate Development Officer
- Ms. Ann CunninghamNon-Executive Non-Independent Director, since 2019$96,226
- Dr. Joanne CurleyIndependent Director$98,726
- Ms. Mary RotunnoIndependent Director$113,726
- Mr. Jon SaxeIndependent Director$118,726
- Mr. Mark McpartlandSenior Vice President - Investor Relations$479,988
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 64
- Environment
- 68
- Social
- 73
- Governance
- 51
- Carbon reduction policy
- No
- Human rights policy
- No
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Vistagen Therapeutics employs 9 full-time staff in South San Francisco.
- The pipeline includes PH94B for social anxiety disorder treatment.
- PH10 is planned for Phase 2b development as a stand-alone treatment.
Weaknesses
- The company has only 9 employees for clinical-stage operations.
- PH94B is preparing for Phase III clinical trials currently.
- AV-101 targets multiple disorders including depressive disorder and epilepsy.
Opportunities
- PH94B has potential to treat multiple anxiety disorders effectively.
- CardioSafe 3D technology predicts potential cardiotoxicity for drug safety.
- AV-101 addresses neuropathic pain and levodopa-induced dyskinesia needs.
Threats
- PH10 faces competition in the depressive disorder market segment.
- AV-101 development for suicidal ideation requires rigorous clinical validation.
- Phase III trials for PH94B involve significant regulatory scrutiny.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.